AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 13 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) has received a $6 million payment following the completion of a multicenter phase II clinical trial of GVAX lung cancer vaccine from the pharmaceutical division of Japan Tobacco, Inc., (JT) in connection with a worldwide collaboration agreement for GVAX lung cancer vaccines.
Encouraging data from this phase II trial demonstrating anticancer activity in advanced stage lung cancer patients were recently updated at the International Conference on Gene Therapy of Cancer. A phase III trial of GVAX lung cancer vaccine is expected to begin in late 2002.
The data reported in late 2001 were updated clinical results from Cell Genesys' phase II GVAX lung cancer vaccine trial which demonstrated a complete tumor response rate of 12% and a median response duration of at least 11 months in 26 patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy. In addition to the responses in patients with advanced disease, eight of the ten patients with early stage lung cancer who received GVAX lung cancer vaccine following surgery, currently remain free of disease with a median follow up time of 12 months.
"We continue to be ...
Source: HighBeam Research, Cell Genesys collaboration yields $6 million payment from Japan...